Corrigendum to "Tetrahydropyridin-4-ylpicolinoylglycines as novel and orally active prolyl hydroxylase 2 (PHD2) inhibitors for the treatment of renal anemia" [Eur. J. Med. Chem. 238 (2022) 114479]
Eur J Med Chem. 2023 Nov 5:259:115692.
doi: 10.1016/j.ejmech.2023.115692.
Epub 2023 Aug 6.
1 Jiangsu Key Laboratory of Drug Design and Optimization, Department of Chemistry, China Pharmaceutical University, Nanjing, 211198, China.
2 Jiangsu Key Laboratory of Drug Design and Optimization, Department of Chemistry, China Pharmaceutical University, Nanjing, 211198, China. Electronic address: zxj@cpu.edu.cn.